explore -WSS

explore

author：comprehensive 2025-08-12 06:42:31 - browse：31

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Diverse clinical trials: Why aren’t we there yet?

focus

WSS

Will the IRA bring competition to the biologics market?

Use doctors trained outside the U.S. to ease the physician shortage

Hospitals consider fixing cancer drug shortages on their own

Undocumented workers face uncertainty as immigration law takes effect in Florida

Undocumented workers face uncertainty as immigration law takes effect in Florida

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

focus

explore

hotspot

Peter Hotez and the public health issue of online harassment

Regeneron agrees to White House price limits on anti

Anesthesiologist group: stop taking Ozempic before surgery

Being 'nonadherent' patient made me a more empathetic doctor

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Long Covid needs a new name — and a new frame

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

White House touts steps to stem shortages of cancer treatments

Bright Health sells Medicare Advantage business to Molina

Food makers tried to stack nutrition panel with preferred experts

focus

How Robert F. Kennedy Jr. distorted vaccine science

Regeneron agrees to White House price limits on anti

Drug cartel violence flares in western Mexico after vigilante leader's killing

Long Covid needs a new name — and a new frame

Prescription digital therapeutics are key to pharma’s future

Fatty liver disease was alleviated by Lilly’s ‘triple

hotspot

focus

focus

focus